Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2 Other hematologic neoplasm 2 Tumor-Agnostic 1 Sarcoma 1 Lymphoid 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Breast 1

Conditions

Prostatic Neoplasms 1

Interventions

Docetaxel 205 Prednisone 151 enzalutamide 128 Gemcitabine 123 Radiotherapy 117 Sunitinib 112 Cisplatin 103 Leuprolide 98 pembrolizumab 96 Abiraterone Acetate 94 bicalutamide 87 Nivolumab 85 Goserelin 83 Sorafenib 80 Paclitaxel 79 Carboplatin 77 Everolimus 72 Bevacizumab 71 Magnetic Resonance Spectroscopy 66 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61 pazopanib 56 radium Ra 223 dichloride 50 Ipilimumab 49 Zoledronic Acid 47 Cyclophosphamide 44 Radiosurgery 43 Filgrastim 42 abiraterone 41 gallium 68 PSMA-11 40 Surveys and Questionnaires 40

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × BI 2536 × Genitourinary × Clear all

NCT00706498 2014-05-16

Phase II Study of BI 2536 in Prostate Cancer

Boehringer Ingelheim

Phase 2 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡